Article
FLT3-targeted treatment for acute myeloid leukemia.
International journal of hematology - 1 Sept 2022
Arai Yasuyuki, Chi SungGi, Minami Yosuke, Yanada Masamitsu
Abstract excerpt
Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are detected in approximately 30% of acute myeloid leukemia (AML). The high frequency of FLT3 mutations, along with their adverse effect on prognosis, makes FLT3 a promising therapeutic target, and has spurred development of FLT3 inhibitors. First-generation inhibitors, including midostaurin and sorafenib, lack specificity for FLT3 and act on multiple...
Topics
- Antineoplastic Agents
- Hematopoietic Stem Cell Transplantation
- Humans
- Leukemia, Myeloid, Acute
- Mutation
- Protein Kinase Inhibitors
- fms-Like Tyrosine Kinase 3